药物重新定位
重新调整用途
医学
背景(考古学)
重症监护医学
药品
药物开发
疾病
观察研究
药理学
内科学
生物
生态学
古生物学
作者
Paolo Gelosa,Laura Castiglioni,Marina Camera,Luigi Sironi
标识
DOI:10.1016/j.bcp.2020.113894
摘要
Cardiovascular disease remains – despite the development of new drugs, devices, and therapeutic strategies – the leading cause of death and disability worldwide. There is therefore a great need to implement the pharmacological armamentarium, considering also the need to balance the therapeutic and the side effects. Furthermore, the best choice among the drug treatment options and reduction of side effects remain urgent problems for studies of cardiovascular disease. In this context, drug repurposing could be an innovative way and opportunity to extend and improve pharmacological tools. Indeed, applying well-established drugs and compounds to new indications, drug repurposing has already been proven efficient and safe in humans. Furthermore, this approach generates lower costs and needs shorter time for approval than the development of a de novo drug. In the current review, we discuss the main evidence for the repurposing in cardiovascular diseases of drugs approved and marketed for other pathologies by reviewing their mechanisms of action and the results reported in observational and then in randomized studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI